BOLT

Bolt Biotherapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1641281Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$8.0M

Net Income FY2025

$(33.0M)

EPS (Basic, as reported)

$-17.85

Net Margin FY2025

-433.7%

ROE FY2025

-125.9%

Total Equity

$27.0M

Shares Out

Business description

Bolt Biotherapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 8

Fiscal yearFY2020⚑FY2021FY2022FY2023FY2024⚑FY2025

Revenue016888

Research & development(40)(76)(73)(62)(57)(29)

General & administrative(9)(18)(23)(23)(18)(14)

Total operating expenses(49)(94)(96)(84)(81)(44)

Operating income(49)(93)(90)(76)(73)(36)

Other income (expense), net(12)(6)27103

Pre-tax income————(63)(33)

Income tax expense000000

Net income(61)(99)(88)(69)(63)(33)

EPS — basic—($2.97)($2.36)($1.83)($1.65)($17.85)

EPS — diluted—($2.97)($2.36)($1.83)($1.65)($17.85)

Shares outstanding — basic (M)2333738382

Shares outstanding — diluted (M)—333738382

⚑ Weighted-average shares changed ×16.50 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ÷20.00 between FY2024 and FY2025 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.